The effect of arginine-vasopressin and its analogues upon the endocochlear potential in the guinea pig.
The effect of arginine-vasopressin (AVP) and its analogues upon the endocochlear potential (EP) was examined in the guinea pig. AVP decreased the EP reversibly and dose-dependently like lysin-vasopressin (LVP). V1 antagonist failed to block the effect of AVP upon the EP. V2 agonist reversibly decreased the EP like AVP. The results suggest that V2 receptors mediate the action of vasopressin on the EP.
Mori
N
N
Department of Otolaryngology, Kagawa Medical School, Osaka University Medical School, Japan.
Shugyo
A
A
Asai
H
H
D000200:Action Potentials / Q000187:drug effects; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology*; D003051:Cochlea / Q000187:drug effects / Q000502:physiology*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D006168:Guinea Pigs; D011945:Receptors, Angiotensin / Q000502:physiology; D017483:Receptors, Vasopressin; D013316:Stria Vascularis / Q000201:enzymology
D011945:Receptors, Angiotensin; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D000262:Adenylyl Cyclases; D003894:Deamino Arginine Vasopressin